Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 22


Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Hematology. 2017 Jan 20:1-7. doi: 10.1080/10245332.2017.1279842. [Epub ahead of print]


Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Br J Haematol. 2016 Oct;175(2):275-280. doi: 10.1111/bjh.14228.


Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Br J Haematol. 2016 May;173(3):404-12. doi: 10.1111/bjh.13975.


Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.

Caimi PF, William BM, Silva Rondon CH, Fu P, Cooper BW, Campagnaro EL, Gerson SL, Reese-Koc J, Fox R, Creger RJ, de Lima M, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1926-31. doi: 10.1016/j.bbmt.2015.06.007.


Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.

Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat U.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1529-31. doi: 10.1016/j.bbmt.2015.04.022.


A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.

Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):428-432.e2. doi: 10.1016/j.clml.2015.02.017.


Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ; Graft-vs-Host Disease Working Committee of the CIBMTR..

Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74. doi: 10.1016/j.bbmt.2014.10.021.


Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ.

Biol Blood Marrow Transplant. 2014 Jul;20(7):960-8. doi: 10.1016/j.bbmt.2014.03.013.


Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.

Lazarus HM, Sommers SR, Arfons LM, Fu P, Ataergin SA, Kaye NM, Liu F, Kindwall-Keller TL, Cooper BW, Laughlin MJ, Creger RJ, Barr PM, Gerson SL, Kaplan D.

Biol Blood Marrow Transplant. 2011 Jul;17(7):970-8. doi: 10.1016/j.bbmt.2011.03.005.


A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer.

Chen WC, Kim J, Kim E, Silverman P, Overmoyer B, Cooper BW, Anthony S, Shenk R, Leeming R, Hanks SH, Lyons JA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):14-20. doi: 10.1016/j.ijrobp.2010.08.051.


Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.

Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW.

Br J Haematol. 2009 Oct;147(1):89-96. doi: 10.1111/j.1365-2141.2009.07836.x.


Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.

Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC.

Am J Hematol. 2009 Aug;84(8):484-7. doi: 10.1002/ajh.21449.


Erythema nodosum in association with newly diagnosed hairy cell leukemia and group C streptococcus infection.

Patel RR, Kirkland EB, Nguyen DH, Cooper BW, Baron ED, Gilliam AC.

Am J Dermatopathol. 2008 Apr;30(2):160-2. doi: 10.1097/DAD.0b013e3181618a8a.


Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults.

van Heeckeren WJ, Fanning LR, Meyerson HJ, Fu P, Lazarus HM, Cooper BW, Tse WW, Kindwall-Keller TL, Jaroscak J, Finney MR, Fox RM, Solchaga L, Forster M, Creger RJ, Laughlin MJ.

Br J Haematol. 2007 Nov;139(3):464-74.


Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome.

Yüksel M, Baron E, Camouse M, Cooper BW, Lazarus HM, Gerson SL, Laughlin MJ, Cooper KD, Gilliam A, Fu P, Stevens S, Koç ON.

Biol Blood Marrow Transplant. 2006 Jun;12(6):665-71.


Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.

van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM, Simic A, Laughlin MJ, Gerson SL, Koç ON.

Br J Haematol. 2006 Jan;132(1):42-55.


Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.

Cooper BW, Radivoyevitch T, Overmoyer BA, Shenk RR, Pham HT, Samuels JR, Parry MP, Silverman P.

Breast Cancer Res Treat. 2006 Jun;97(3):311-8.


Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.

Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A.

Biol Blood Marrow Transplant. 2005 May;11(5):389-98.


High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.

Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.

Biol Blood Marrow Transplant. 2005 Jan;11(1):13-22.


A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.

Cooper BW, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM, Koc ON, Creger RJ, Pearson G, Nowell GM, Gosky D, Ingalls ST, Hoppel CL, Gerson SL.

Clin Cancer Res. 2004 Oct 15;10(20):6830-9.

Items per page

Supplemental Content

Loading ...
Support Center